Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer research study using special immune cells. The body has different …

fludarabine
leukemia
gilbert's syndrome
measurable disease
anthracycline
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of Venetoclax (ABT-199) Consolidation for Patients Currently Receiving Ibrutinib or Acalabrutinib for High-risk CLL

This is a single center, open-label, phase II study of venetoclax (ABT-199) added to ibrutinib or acalabrutinib in patients with high-risk CLL who have received at least 12 months of ibrutinib or acalabrutinib monotherapy. The study will estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable CLL …

neutrophil count
TP53
residual tumor
venetoclax
lymphoid leukemia
  • 58 views
  • 18 Oct, 2022
  • 1 location
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in …

follicular lymphoma
indolent lymphoma
neutrophil count
fludeoxyglucose f-18
ct scan
  • 194 views
  • 07 Sep, 2021
  • 7 locations
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has …

tumor cells
leukemia
gilbert's syndrome
blood transfusion
progressive disease
  • 40 views
  • 07 Jul, 2022
  • 8 locations
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

the treatment of refractory and relapsed AML. The strong synergistic anti-cancer effect of HDACi combined with Cladribine has been shown in many cancers such as B-cell chronic lymphocytic

remission
refractory acute myeloid leukemia (aml)
cladribine
induction chemotherapy
adult acute myelogenous leukemia
  • 0 views
  • 18 May, 2022
  • 1 location
Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated …

follicular lymphoma
leukemia
lymphocytic leukemia
diffuse large b-cell lymphoma
cyclin d1
  • 1 views
  • 07 Oct, 2022
  • 3 locations
A Phase I/II,Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies

This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).

leukemia
gilbert's syndrome
bone marrow infiltration
blood transfusion
ct scan
  • 72 views
  • 12 Oct, 2022
  • 27 locations
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

white blood cells
leukemia
indolent lymphoma
measurable disease
chemotherapy regimen
  • 0 views
  • 24 Mar, 2022
  • 6 locations
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

b-cell small lymphocytic lymphoma
leukemia
monoclonal antibodies
TP53
measurable disease
  • 4 views
  • 07 Oct, 2022
  • 12 locations
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL

The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab in Japanese patients with relapsed, progressive or refractory B-cell lymphomas and Japanese patients with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior SOC. The trial consists of two parts: Part 1, …

prednisone
vincristine
diffuse large b-cell lymphoma
doxorubicin
ct scan
  • 0 views
  • 07 Oct, 2022
  • 11 locations